Validation and clinical utility of prostate cancer biomarkers.
about
New blood markers detection technology: A leap in the diagnosis of gastric cancerInvestigating intratumour heterogeneity by single-cell sequencingBlood-based Tumor Markers in Lung CancerBlood-based analyses of cancer: circulating tumor cells and circulating tumor DNATrial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3Emerging proteomics biomarkers and prostate cancer burden in Africa.RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance.Method validation of circulating tumour cell enumeration at low cell counts.Prostate cancer marker panel with single cell sensitivity in urine.Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error.Biomarker development in the context of urologic cancersThe Use of a New CellCollector to Isolate Circulating Tumor Cells from the Blood of Patients with Different Stages of Prostate Cancer and Clinical Outcomes - A Proof-of-Concept Study.Enhanced diagnostic accuracy for quantitative bone scan using an artificial neural network system: a Japanese multi-center database project.Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer.Circulating tumor cells: advances in isolation and analysis, and challenges for clinical applications.Circulating tumor cells as promising novel biomarkers in solid cancers.Circulating tumour cells-monitoring treatment response in prostate cancer.Nucleic acid-based tissue biomarkers of urologic malignancies.Biomarkers in saliva for the detection of oral squamous cell carcinoma and their potential use for early diagnosis: a systematic review.Circulating tumor cell counts/change for outcome prediction in patients with extensive-stage small-cell lung cancer.Positron emission tomography (PET) imaging of prostate cancer with a gastrin releasing peptide receptor antagonist--from mice to men.Molecular image-directed biopsies: improving clinical biopsy selection in patients with multiple tumorsBone scan index: A new biomarker of bone metastasis in patients with prostate cancer.Improving circulating tumor cells enumeration and characterization to predict outcome in first line chemotherapy mCRPC patients.Cancer genetics: the origin and evolution of an ancient cancer.CTC-derived AR-V7 detection as a prognostic and predictive biomarker in advanced prostate cancer.Bone scan index of the jaw: a new approach for evaluating early-stage anti-resorptive agents-related osteonecrosis.Circulating tumor cells in genitourinary tumors.Integrated Analysis of Multiple Biomarkers from Circulating Tumor Cells Enabled by Exclusion-Based Analyte Isolation.Multigene profiling of CTCs in mCRPC identifies a clinically relevant prognostic signature.Circulating tumour cells go green.Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer
P2860
Q26774503-A147995A-A5DC-4F4B-AF7B-9553BECFD599Q27015460-B9F5FB9F-07CA-4BF5-8F12-15DF458E28FCQ28072736-21D3B641-4B38-455D-8DDD-72C249A3F40AQ28239638-7B3DD374-77A6-4883-975B-CD96EEA10359Q30277291-8FF2B38A-8F0C-4F4D-9F22-10849DCA7871Q33914221-3E1D24BE-B9C5-4E5A-BA58-4A76DFE62C89Q34494714-80A72F6C-6513-4850-AFDC-F88D3000E99DQ34984977-39ABFE56-A812-4F36-B845-08A2F4399A81Q35582373-6E07EC5E-3CD5-4E22-A209-D06DC2AD74CFQ35678391-8DA1E56A-AFBB-467F-B1B6-52D3BDED7886Q35906352-62D8E743-A19F-4140-AADD-1D9EE161A3A5Q36091649-5F87A64F-BBD6-47A1-AF32-BE96EF0CA3A6Q37425136-18403BEF-DEB8-4209-88E0-6F9732C05F64Q37550588-E357D39C-2ADA-4905-99AE-7D3587F41FDFQ37626062-2DCC9D13-8D73-401E-B3B0-E8E05FF60F88Q38196920-4569AA76-1D7B-4B32-9B18-260BB767850FQ38211361-53D9A9CC-93DA-43DE-A04C-B9934508EA0EQ38216131-ACEFF3DB-9185-4A44-AA25-97876CCDAD0EQ38636192-C943EBDE-569B-42C3-A2B6-69FDA32F7282Q38912917-0BFC21D9-B55A-4A8E-AA25-322C982DE5C5Q39242936-7441D1B1-CA57-4718-AD8A-DAC5B1350044Q39330511-62BE1E67-A8C4-4BBC-96B3-C33961DDBE5CQ39337696-BCE93F60-8AAF-420B-91FD-74BDB55DC1EAQ41550939-6FAAB507-85D2-4C76-BDF4-DC70114BC084Q47670490-789FE2B1-2C81-444B-90AF-BDF336FD023AQ47740995-3825B36F-D1B9-4E75-AA7A-53460BD3AB95Q48136150-6F06C24A-76B8-448C-AA5D-33F22D099C0AQ49557521-CAE395D4-D67F-41A5-B779-8AEE782AFA49Q49610945-6CAEE09F-D071-4843-B721-C6DFB19C83EBQ49913687-50721A43-4D7A-4B3E-8400-4765035C01ABQ50447123-E16E492D-2A6C-420C-8EE0-C5F125AD393CQ57492447-8577712E-1DFD-4A01-9E33-23F0D0D3B6D0
P2860
Validation and clinical utility of prostate cancer biomarkers.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Validation and clinical utility of prostate cancer biomarkers.
@en
type
label
Validation and clinical utility of prostate cancer biomarkers.
@en
prefLabel
Validation and clinical utility of prostate cancer biomarkers.
@en
P2093
P2860
P1476
Validation and clinical utility of prostate cancer biomarkers
@en
P2093
Glenn Heller
Howard I Scher
Steven Larson
P2860
P304
P356
10.1038/NRCLINONC.2013.30
P407
P577
2013-03-05T00:00:00Z